Previous 10 | Next 10 |
Immunic Receives Notice of Allowance for United States Patent Protecting the Treatment of Relapsing Multiple Sclerosis with Vidofludimus and Its Salts PR Newswire NEW YORK , Nov. 2, 2023 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology co...
Immunic Inc. (IMUX) is expected to report $-0.55 for Q3 2023
Immunic to Participate in Scientific and Industry Conferences in November PR Newswire NEW YORK , Oct. 26, 2023 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule ...
--News Direct-- Immunic Inc (NASDAQ:IMUX) Chief Scientific Officer Hella Kohlhof speaks to Thomas Warner at the Proactive London after returning from MSMilan2023, the 9th Joint ECTRIMS-ACTRIMS meeting. She shares some of the main talking points from the event, noting keen interest in form...
2023-10-19 19:15:23 ET Summary Positive interim analysis from its phase 2 CALLIPER study achieved, showing a statistically significant reduction in neurofilament light chain (NfL) in progressive multiple sclerosis patients when given vidofludimus calcium. Vidofludimus calcium perf...
Immunic Presents Data From Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Ulcerative Colitis at the United European Gastroenterology Week 2023 PR Newswire NEW YORK , Oct. 16, 2023 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology compa...
Immunic Presents Data From Phase 1b Clinical Trial of IMU-856 in Celiac Disease at the United European Gastroenterology Week 2023 PR Newswire NEW YORK , Oct. 15, 2023 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a c...
Immunic Presents Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis at MSMilan2023: The 9th Joint ECTRIMS-ACTRIMS Meeting PR Newswire – Improvement in Serum Neurofilament Light Chain (NfL) Observed in Both Treatment Arms o...
--News Direct-- Immunic Inc (NASDAQ:IMUX) President and CEO Dr Daniel Vitt speaks to Thomas Warner from Proactive after the biotechnology company announced encouraging interim data from its phase II CALLIPER trial assessing the potential of its treatment for progressive multiple sclerosis...
2023-10-10 10:09:18 ET DENVER, Colo., Oct. 10, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual volume; SMX (Security Matters) (NASDAQ: SMX), Immunic (NASDAQ: IMUX), Intrusion (NASDAQ: INTZ), SuperCom (NASDAQ: SPC...
News, Short Squeeze, Breakout and More Instantly...
Immunic Appoints Jason Tardio as Chief Operating Officer and President PR Newswire – Former Novartis and Biogen Executive Brings Extensive Multiple Sclerosis Drug Commercialization Experience to Immunic – – Werner Gladdines, Current Vice President,...
--News Direct-- Immunic Inc CEO Daniel Vitt joined Steve Darling from Proactive to discuss the ongoing challenges and recent developments in treating multiple sclerosis (MS). This interview took place in conjunction with World MS Day, a day dedicated to raising global awareness about this...
Immunic to Participate in Industry and Scientific Conferences in June PR Newswire NEW YORK , May 28, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule thera...